Scarica l'app Stockscreener
138.99
2.18%
-3.10
Dopo l'orario di chiusura:
141.21
2.22
+1.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration - Yahoo Finance
Sumitomo Mitsui Trust Group Reduces Gilead Sciences Stake - National Today
Greenup Street Wealth Management Boosts Gilead Sciences Stake - National Today
Greenup Street Wealth Management LLC Purchases Shares of 19,408 Gilead Sciences, Inc. $GILD - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $401.25 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Massachusetts Financial Firm Boosts Gilead Sciences Holdings - National Today
Massachusetts Financial Services Co. MA Grows Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area - CSRwire
Gilead Sciences (GILD) to acquire Tubulis for $5B to strengthen oncology pipeline - MSN
Does Tempus AI’s (TEM) Deeper Gilead Tie Mark a Shift in Its Platform Strategy? - simplywall.st
Ritholtz Wealth Management Boosts Gilead Sciences Stake - National Today
Ritholtz Wealth Management Acquires 7,865 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead’s Tubulis Deal Recasts Oncology Ambitions And HIV Reliance Risks - Yahoo Finance
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Taxation With Representation: Goodwin, CMS, Wilson Sonsini - Law360
AHF Slams Gilead for Role in Florida AIDS Drug Crisis - Business Wire
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $175.00 - MarketBeat
Gilead projects $107M Q1 earnings headwind due to recent R&D deals - MSN
Cantor Fitzgerald Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $115.00 - MarketBeat
Gilead exercises option to license Kymera’s KT-200 - BioWorld News
Tempus AI stock rises on Gilead collaboration deal - Investing.com
Spirepoint Private Client LLC Has $9.37 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Tempus AI stock rises on Gilead collaboration deal By Investing.com - Investing.com South Africa
RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders - Yahoo Finance
Rx Rundown: Gilead Sciences, Jeito Capital, Neurocrine Biosciences and more - Medical Marketing and Media
Why Is Tempus AI Stock Gaining Friday?Tempus AI (NASDAQ:TEM) - Benzinga
Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline - Yahoo Finance
Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - Investing News Network
Tempus AI expands collaboration with Gilead Sciences By Investing.com - Investing.com Australia
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines - MedCity News
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline - Benzinga
Gilead Expands Oncology Pipeline With $5B Tubulis Deal - Yahoo Finance
Focus on HIV therapies propels Gilead Sciences stock consolidation amid mixed technical momentum - Traders Union
Gilead Sciences Sees Institutional Investment Boost - National Today
Gilead Sciences (GILD) Secures Exclusive Rights to KT-200 from K - GuruFocus
Gilead price target raised to $155 from $152 at Truist - Yahoo Finance
Tempus AI expands collaboration with Gilead Sciences - Investing.com
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE - Yahoo Finance
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise - Business Wire
Gilead exercises option on Kymera’s CDK2 degrader for $45M By Investing.com - Investing.com India
OFI Invest Asset Management Acquires 470,804 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead exercises option on Kymera’s CDK2 degrader for $45M - Investing.com
MH & Associates Securities Management Corp ADV Invests $4.57 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - The Manila Times
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 ... - Bluefield Daily Telegraph
8,451 Shares in Gilead Sciences, Inc. $GILD Bought by Jackson Square Capital LLC - MarketBeat
Hiltzik: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people - AOL.com
Germany: Gilead significantly expanding ADC capabilities with agreement to acquire Tubulis for up to US$5bn - Investors in Healthcare
Commentary: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people - Los Angeles Times
Gilead to pay up to $5bn for antibody-drug conjugates push - Life Sciences Intellectual Property Review
Gilead Sciences (GILD) Advances But Underperforms Market: Key Facts - Yahoo Finance
Gilead's Commitment to Bridging the Unmet HIV Treatment Gap - Gilead Sciences
Gilead Sciences Inc. stock rises Wednesday, still underperforms market - MarketWatch
Gilead to Buy Cancer Biotech Tubulis in $5B Deal - marketscreener.com
Gilead Sciences (GILD) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
With 3 quick buyouts, Gilead leans into its latest transformation - BioPharma Dive
Gilead Agrees $5 Billion Tubulis Acquisition To Expand Cancer Dr - GuruFocus
Gilead takes another big swing at expanding beyond HIV - Endpoints News
Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities - BioSpace
Truist raises Gilead Sciences stock price target on M&A activity - Investing.com
TD Cowen reiterates Buy on Gilead stock after recent acquisitions - Investing.com
BMO reiterates Gilead Sciences stock rating on Tubulis acquisition - Investing.com
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $165 to $175 - Moomoo
Oppenheimer Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $165 - Moomoo
Cantor Fitzgerald reiterates Gilead Sciences stock rating on Yeztugo beat - Investing.com
Gilead Sciences Is Doubling Down On Acquisitions (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating - TipRanks
Sivik Global Healthcare LLC Buys Shares of 25,000 Gilead Sciences, Inc. $GILD - MarketBeat
BMO Capital Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $174 - Moomoo
Oppenheimer reiterates Gilead stock rating on acquisition strategy - Investing.com
Gilead strengthens ADC capabilities with $5bn Tubulis acquisition - European Pharmaceutical Review
0.21%
1.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):